KEGG   PATHWAY: map07045
Entry
map07045          Drug      Pathway                                
Name
Antineoplastics - protein kinase inhibitors
Class
Pathway map
map07045  Antineoplastics - protein kinase inhibitors
map07045

Compound
D01441  Imatinib mesylate (USAN)
D01977  Gefitinib (JP18/USAN/INN)
D02714  Everolimus (JAN/USAN/INN)
D03218  Axitinib (JAN/USAN)
D03252  Bosutinib (USAN)
D03257  Trastuzumab (USAN/INN)
D03350  Canertinib dihydrochloride (USAN)
D03455  Cetuximab (USAN/INN)
D03658  Dasatinib (JAN/INN)
D04014  Enzastaurin hydrochloride (JAN/USAN)
D04023  Erlotinib hydrochloride (JAN/USAN)
D04024  Lapatinib ditosylate (USAN)
D04696  Lestaurtinib (USAN/INN)
D05029  Midostaurin (JAN/USAN/INN)
D05350  Panitumumab (USAN/INN)
D05380  Pazopanib hydrochloride (JAN/USAN)
D05446  Pertuzumab (USAN/INN)
D05819  Semaxanib (USAN/INN)
D06005  Tandutinib (USAN/INN)
D06068  Temsirolimus (JAN/USAN/INN)
D06272  Sorafenib tosylate (USAN)
D06285  Vatalanib (USAN/INN)
D06402  Sunitinib malate (JAN/USAN)
D06407  Vandetanib (JAN/USAN/INN)
D06413  Nilotinib hydrochloride hydrate (JAN)
D06414  Dasatinib (USAN)
D06678  Motesanib (USAN)
D07907  Erlotinib (INN)
D08066  Imatinib (INN)
D08108  Lapatinib (INN)
D08524  Sorafenib (USAN/INN)
D08552  Sunitinib (INN)
D08947  Motesanib diphosphate (USAN)
D08953  Nilotinib (USAN/INN)
D09724  Afatinib (USAN/INN)
D09728  Bosutinib hydrate (JAN)
D09731  Crizotinib (JAN/USAN/INN)
D09733  Afatinib dimaleate (USAN)
D09955  Quizartinib (USAN/INN)
D09956  Quizartinib dihydrochloride (USAN)
D09959  Ruxolitinib (USAN/INN)
D09960  Ruxolitinib phosphate (JAN/USAN)
D09980  Trastuzumab emtansine (USAN/INN)
D10202  Bafetinib (USAN)
Reference
PMID:15710326
  Authors
Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, Kung AL, Mestan J, Daley GQ, Callahan L, Catley L, Cavazza C, Azam M, Neuberg D, Wright RD, Gilliland DG, Griffin JD.
  Title
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.
  Journal
Cancer Cell 7:129-41 (2005)
DOI:10.1016/j.ccr.2005.01.007
Reference
PMID:17327610
  Authors
Chow LQ, Eckhardt SG.
  Title
Sunitinib: from rational design to clinical efficacy.
  Journal
J Clin Oncol 25:884-96 (2007)
DOI:10.1200/JCO.2006.06.3602
Reference
PMID:17956080
  Authors
Veach DR, Namavari M, Pillarsetty N, Santos EB, Beresten-Kochetkov T, Lambek C, Punzalan BJ, Antczak C, Smith-Jones PM, Djaballah H, Clarkson B, Larson SM.
  Title
Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.
  Journal
J Med Chem 50:5853-7 (2007)
DOI:10.1021/jm070342g
Reference
PMID:15685537
  Authors
Debiec-Rychter M, Cools J, Dumez H, Sciot R, Stul M, Mentens N, Vranckx H, Wasag B, Prenen H, Roesel J, Hagemeijer A, Van Oosterom A, Marynen P.
  Title
Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.
  Journal
Gastroenterology 128:270-9 (2005)
DOI:10.1053/j.gastro.2004.11.020
Reference
PMID:17419150
  Authors
von Mehren M.
  Title
Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors.
  Journal
Clin Colorectal Cancer 6 Suppl 1:S30-4 (2006)
DOI:10.3816/CCC.2006.s.005
Reference
PMID:17699867
  Authors
Guo T, Agaram NP, Wong GC, Hom G, D'Adamo D, Maki RG, Schwartz GK, Veach D, Clarkson BD, Singer S, DeMatteo RP, Besmer P, Antonescu CR
  Title
Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.
  Journal
Clin Cancer Res 13:4874-81 (2007)
DOI:10.1158/1078-0432.CCR-07-0484

DBGET integrated database retrieval system